Biotech Values

[biocqr]

It was disclosed in the Prospectus filed on June 24...

https://www.sec.gov/Archives/edgar/data/1479290/000119312520177782/d922558d424b3.htm

Interests of Revance Directors and Executive Officers in the Merger (see page 109)

In considering the recommendation of the Revance board with respect to the Merger, you should be aware that certain members of the Revance board and certain executive officers of Revance have interests in the Merger that may be different from, or in addition to, the interests of Revance stockholders, which include:

Mark Foley, Revance’s Chief Executive Officer and a member of the Revance board, previously served on the HintMD board and was the Chairman of the board of directors from October 2017 until May 2020 and is a holder of 817,383 shares of HintMD common stock. Mr. Foley is also the trustee of the Foley Family Trust, which holds 121,182 shares of HintMD Series A-1 preferred stock and 36,195 shares of HintMD Series B-2 preferred stock.

Each of the HintMD board and Revance board was aware of these interests and considered them, among other matters, in approving the Merger Agreement and, in the case of the HintMD board, in making its recommendation that HintMD stockholders adopt the Merger Agreement.